

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI880156

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AUTO INJECTION TECHNOLOGIES LLC	03/11/2025
RECEIVING PARTY DATA	
Company Name:	SANOFI
Street Address:	46 avenue de la Grande Armée
City:	Paris
State/Country:	FRANCE
Postal Code:	75017
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14364242
CORRESPONDENCE DATA	
Fax Number:	6122889696
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(612)335-5070
Email:	colicchio@fr.com,APSI@fr.com
Correspondent Name:	Michael A. Jandron
Address Line 1:	Fish & Richardson P.C.
Address Line 2:	P.O. Box 1022
Address Line 4:	Minneapolis, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	46567-0204US1
NAME OF SUBMITTER:	Lauren Colicchio
SIGNATURE:	/Lauren Colicchio/
DATE SIGNED:	03/11/2025
Total Attachments: 3	
source=AIT ASSIGNMENT ~ EXHIBIT D#page1.tiff	
source=AIT ASSIGNMENT ~ EXHIBIT D#page2.tiff	
source=AIT ASSIGNMENT ~ EXHIBIT D#page3.tiff	

PATENT ASSIGNMENT

This patent assignment (“**Assignment**”) is entered into as of 11 March 2025 (the “**Effective Date**”) by and between **SANOFI** (“**SANOFI**”), a French corporation having a principal place of business at 46 avenue de la Grande Armée, 75017 Paris, France (“**Assignee**”), and **AUTO INJECTION TECHNOLOGIES LLC**, a Texas-based entity having a principal place of business at 104 East Houston Street Suite 140 Marshall TX 75670 USA (“**Assignor**”), and assigns all of Assignor’s right, title, and interest in and to the following (collectively, the “**Assigned Patent Rights**”):

For good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby irrevocably sell, assign, transfer, and convey to Assignee, as the Effective Date, all of the Assignor’s existing right, title and interest for the United States of America and its territorial possessions, and all foreign countries including all rights of priority, in inventions disclosed in:

- (a) the patents and patent applications and any terminally disclaimed to or from such patents (U.S. or Foreign) (the “**Patents**”) solely owned by Assignor and expressly identified on Exhibit D, together with;
- (b) future applications for patents under U.S. law or regulation or of any foreign country with respect to the patentable inventions filed by Assignee from which any of the foregoing arise, including without limitation, divisions, continuations, continuations-in-part, substitutions, reexaminations, reissues, extensions, continuing prosecution application, requests for continuing examinations, registrations of any of the Patents and foreign counterparts therefrom (collectively, “**Assigned Patents**”);
- (c) rights to apply in any or all countries of the world for future patents, certificates of invention, utility models, industrial design protections, design patent protections, or other future governmental grants or issuances of any type related to the Patents; and
- (d) all causes of action, enforcement rights, and remedies of any kind arising under any such Assigned Patent prior to, on or after the Effective Date of this Agreement and/or any of the items described in either of the foregoing categories (b) or (c) , including, without limitation, all causes of action, enforcement rights and all other rights to seek and obtain any other remedies of any kind for past, current, and future infringement and all claims for damages by reason of past, present or future infringement or other unauthorized use of such Assigned Patents with the right to sue for and collect such damages.

Assignor hereby authorizes the respective patent office or governmental agency in each jurisdiction to issue any and all future patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon any of the Assigned Patent Rights in the name of Assignee, as the assignee to the entire interest therein. This Assignment of Patent Rights will inure for the benefit of any permitted successors or assigns of Assignee.

Assignor will, at the reasonable request of Assignee, take all reasonable steps necessary and proper, to confirm the assignment to Assignee of the Assigned Patent Rights pursuant to this Assignment of Patent Rights, including without limitation, the execution, acknowledgment, and recordation of specific assignments, oaths, declarations, and other documents on a country-by-country basis, to assist Assignee in obtaining and perfecting the Assigned Patent Rights.

IN WITNESS WHEREOF, Assignor has caused its duly authorized representatives to execute this Assignment.

AUTO INJECTION TECHNOLOGIES LLC (“THE ASSIGNOR”)

By: Deepak Kumar Sharma

Name: Deepak Sharma

Title: Managing Director

Date: 11th March 2025

Exhibit D**PATENTS & APPLICATIONS**

Two (2) patent families, and their family members including any divisional, continuation, continuation-in-part, reissue, reexamination, utility model, foreign counterpart, parent or extension of any patent or application and the inventions contained therein, including the right to file for such inventions in the United States and foreign countries as set forth in this Exhibit D, any patents or patent applications whose priority is based upon such patents and patent applications, and any patents that have been named in any terminal disclaimer of any patent included in this Exhibit are listed below. Furthermore, to the extent any family members or INPADOC members (including any expired patents) are not expressly listed below, Seller conveys any rights that it may have in those unlisted members, including the right to sue for past infringement, as if fully set forth in the list below.

PATENT LIST

Publication Number (Representative US family member)	Family
US9511194B2	EP2793980 (CH, DE, DK, FR, GB, LI); CNZL201280069211.X; HK1198581; JP6043806
US9827381B2	US10,653,851; US12,076,541; US-2024-0390604-A1 (PENDING) ; EP2793981 (CH, DE, DK, FR, GB, LI); EP3384944 (CH, DE, DK, FR, GB, LI, SE); CNZL201280069210.5; HK1198518; JP6043805